Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20101893 | 1.00 | ABCB11 (0.37) | ABCB11OPRM1ALDH1A1MAPTHPGD | |
| SCHEMBL22508294 | 1.00 | ABCB11 (0.37) | ABCB11OPRM1ALDH1A1MAPTHPGD | |
| SCHEMBL20101879 | 0.89 | ALDH1A1 (0.34) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL10444593 | 0.89 | ALDH1A1 (0.34) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL10444530 | 0.86 | NPC1 (0.32) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL10444368 | 0.86 | ALDH1A1 (0.32) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL19940393 | 0.85 | ABCB11 (0.34) | ABCB11OPRM1ALDH1A1MAPTHPGD | |
| SCHEMBL19334859 | 0.84 | ALDH1A1 (0.30) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL10444448 | 0.84 | ALDH1A1 (0.30) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL10444449 | 0.84 | ALDH1A1 (0.30) | ALDH1A1MAPTHPGDALOX12TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177487-A1 | FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS | NIKANG THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2020205832-A1 | FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020205835-A1 | FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177487-A1 | FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS | PDXK, PNPO, CDKN1A | ABCB11 4131/4885OPRM1 2451/4885ALDH1A1 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.